Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
O95274
UPID:
LYPD3_HUMAN
Alternative names:
GPI-anchored metastasis-associated protein C4.4A homolog; Matrigel-induced gene C4 protein
Alternative UPACC:
O95274; Q9UJ74
Background:
Ly6/PLAUR domain-containing protein 3, also known as GPI-anchored metastasis-associated protein C4.4A homolog and Matrigel-induced gene C4 protein, plays a crucial role in cell migration and may interact with the urothelial cell-matrix. Its involvement in tumor progression highlights its significance in cancer biology.
Therapeutic significance:
Understanding the role of Ly6/PLAUR domain-containing protein 3 could open doors to potential therapeutic strategies. Its pivotal role in cell migration and tumor progression makes it a target of interest for developing novel cancer treatments.